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UNRESOLVED QUESTIONS IN RHEUMATOLOGY
Motion for Debate: The Data Support Evidence-Based Management
Recommendations for Cardiovascular Disease in Rheumatoid Arthritis
Daniel H. Solomon (Initiator),1 Mike J. L. Peters2 and Michael T. Nurmohamed (In Support),2 and
Will Dixon (In Opposition)3
Presentation of the debate, Dr. Solomon: Introduction to
the motion
Cardiovascular disease (CVD) is a major source
of morbidity and mortality in rheumatoid arthritis (RA).
While we know much about the epidemiology and
biology of this association, less is known about the
treatment. This debate focuses on the management of
CVD in RA: Do we know enough to set forth evidence-
based recommendations? Underpinning this debate are
many challenging scientific and clinical issues. First,
should management focus on traditional cardiovascular
risk factors or on inflammation? Second, should man-
agement of traditional cardiovascular risk factors be
tailored to patients with RA, modifying treatment
thresholds and targets, or are general population recom-
mendations adequate? Third, should RA treatment be
tailored to patients at risk of CVD?
While these questions cannot be decided by a
debate, our guest debaters have brought evidence to
bear on many aspects of these topics. We are sure that
you will enjoy the spirited back and forth and will come
away with your own opinion of these issues.
In support, Drs. Peters and Nurmohamed:
Cardiovascular risk prevention should constitute a key
goal of management in RA
Cardiovascular disease is a major source of mor-
bidity and mortality in RA and may equal the (contem-
porary) CVD burden in diabetes mellitus, a well-
established risk factor for CVD (1–4). Currently,
cardiovascular risk in diabetes mellitus is substantially
lower than during previous decades as a result of
effective implementation of strategies to accomplish
good glycemic control and, in particular, optimal cardio-
vascular risk management, with statin treatment and
blood pressure reduction being key drivers of this effect
(5). In RA, the magnitude of CVD has not appreciably
changed over the last decades (6,7). Despite this well-
established higher cardiovascular risk, a significant pro-
portion of RA patients still receive no or suboptimal
cardiovascular risk management (8–10).
Based on this evidence, we can no longer bury
our heads in the sand and pretend that cardiovascular
risk management should not be part of our agenda.
Cardiovascular risk prevention (i.e., targeting preventive
strategies toward high-risk individuals) should constitute
a key goal of management in RA. A task force of the
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European League Against Rheumatism (EULAR) has
provided evidence- and expert opinion–based recom-
mendations to help clinicians assess and control cardio-
vascular risk in RA (11). But, who should be screened,
how often, and by whom? Which CVD risk prediction
chart should be used? And, what should be the targets or
thresholds for treatment with statins and antihyperten-
sive agents?
In RA, well-established cardiovascular risk fac-
tors, such as smoking, dyslipidemia, hypertension, dia-
betes mellitus, and decreased physical activity, occur
more frequently (12–14). With information on age, sex,
smoking status, lipid levels, and blood pressure, the
10-year absolute risk of a (fatal) cardiovascular event
can be calculated with the use of established CVD risk
prediction charts (e.g., the Systematic Coronary Risk
Evaluation [SCORE] or the Framingham Risk Score)
(15,16). Cardiovascular risk management can be easily
incorporated into routine visits by adding the measure-
ment of blood pressure and nonfasting total cholesterol
and high-density lipoprotein (HDL) cholesterol levels to
routine blood testing (17). Of note, recent observations
support the use of the total cholesterol–to–HDL choles-
terol ratio as the most stable prognostic cardiovascular
indicator in RA (18).
All RA patients should receive evidence-based
advice with regard to smoking, physical activity, and
weight control, and if required based on the absolute
cardiovascular risk, adequate management of that risk.
Similarly, we underscore the need to assess cardio-
vascular risk factors in all RA patients, and we encour-
age clinicians to initiate statin treatment and blood
pressure reduction according to national guidelines to
reduce the cardiovascular risk. One could argue that
we should await intervention trials with statins and/or
antihypertensive agents and CVD end points in RA
before conclusions about their efficacy can be reached.
However, the efficacy of statins and their reduction of
clinical end points in RA are probably at least equiv-
alent to their effects in the general population (19,20).
Indeed, the effects of statins as well as some anti-
hypertensive agents (i.e., angiotensin-converting en-
zyme inhibitors and angiotensin blockers) might be
more pronounced in RA, since their additional benefi-
cial effects include antiinflammatory properties (21,22).
Withholding treatment of proven efficacy (i.e., statins
and/or antihypertensive agents) from RA patients, who
are already known to be at increased cardiovascular risk,
is unethical.
So far, there is no substantial evidence for the use
of lower treatment targets for statins and/or antihyper-
tensive agents in RA as compared with those used in the
general population. There is no indication for the use of
aspirin for primary prevention of CVD in RA.
To ensure sufficient uptake of cardiovascular risk
prevention, we have recommended that patients receive
a yearly cardiovascular risk assessment (11), but we
recognize that in patients with low cardiovascular risk
who have low levels of disease activity, a lower frequency
of assessment could be adopted.
Traditional cardiovascular risk factors, however,
account for only part of the excess cardiovascular risk in
RA (22). Inflammation is also important, as it acceler-
ates atherosclerosis, either directly or via effects on
cardiovascular risk factors (23). Hence, tight disease
control and adequate suppression of the inflammatory
process is crucial for lowering CVD risk in RA. Early
and effective antirheumatic treatment has been shown
to be associated with a lower cardiovascular risk, with
methotrexate and tumor necrosis factor  (TNF)–
blocking therapy having the best available data, accept-
ing that even here, we lack clinical trials showing defin-
itive proof (24,25). Interestingly, it is possible that
cardiovascular risk is reduced only in patients who
respond to TNF-blocking therapy (26).
One could argue that the introduction of the
current powerful biologic therapies will neutralize the
excess cardiovascular risk in RA, making cardiovascular
risk management redundant. Data to support this notion
are lacking, however, and recent risk estimates still
demonstrate an 50% increased risk of CVD. More-
over, in sharp contrast to the much cheaper and more
widely tested generic lipid- and blood pressure–lowering
agents (e.g., in Europe, simvastatin costs at little as €5
per year, compared to more than €10,000 per year for
TNF-blocking agents), these new agents are very ex-
pensive and are not effective in 30% of RA patients
(27). In addition, despite the ability to strongly suppress
disease activity, systemic levels of cytokines sometimes
remain high relative to those in non-RA patients. Hence,
even RA patients receiving such treatment may still be at
elevated risk of CVD.
Nonsteroidal antiinflammatory drugs (NSAIDs),
coxibs, and corticosteroids may influence cardiovascular
risk in two competing ways. NSAIDs and coxibs exert
prothrombotic effects, while corticosteroids have dele-
terious effects on lipids, insulin resistance, blood pres-
sure, and obesity (28,29). In contrast, these drugs may
actually reduce cardiovascular risk by suppressing in-
flammation, which may improve mobility. Yet, conclu-
sive evidence is not available. With these agents, we
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recommend the use of the lowest dose possible for the
shortest period possible.
Given the complex interplay between disease
activity, cardiovascular risk, and the effect of antirheu-
matic treatment, rheumatologists are well positioned to
perform cardiovascular risk assessments, considering
that blood samples need to be obtained anyway and
blood pressure measurement is noninvasive. Alterna-
tively, cardiovascular risk management could be done in
coordination with primary care physicians, who are
experts in this process.
Which risk scoring models should be used? We
acknowledge that a CVD risk prediction chart is lacking
for RA and that calibration of existing risk prediction
charts for RA has not been done. There are several
options for dealing with this. First, we can use existing
CVD risk prediction charts until a model has been
developed that is appropriate for RA. This will take
many years, however, and in the meantime, many pa-
tients will receive suboptimal cardiovascular risk man-
agement because existing CVD risk prediction charts
underestimate the true cardiovascular risk in RA (30).
Second, we can use lower treatment targets for all RA
patients, but evidence to support this notion is lacking.
Moreover, the use of lower treatment targets is expen-
sive and will increase the likelihood of patients’ being
harmed by the therapy. Third, the existing risk predic-
tion charts are adapted in such a way that patients with
an increased cardiovascular risk receive management.
The EULAR task force thought this last option
was the most appropriate and therefore recommended a
multiplication factor. The task force selected 3 prognos-
tic CVD markers to identify patients at highest risk of
developing CVD: disease duration 10 years, presence
of rheumatoid factor (RF) and/or anti–cyclic citrulli-
nated peptide antibodies, and presence of severe disease
(e.g., extraarticular manifestations). When patients meet
at least 2 of these criteria, the risk estimate calculated
with an existing CVD risk prediction chart should be
multiplied by a factor of 1.5. For example, consider a
60-year-old female patient with RA who smokes and has
a total cholesterol level of 6.8 mmoles/liter, an HDL
cholesterol level of 1.1 mmoles/liter, and a systolic blood
pressure of 170 mm Hg. According to the SCORE
model (https://escol.escardio.org/Heartscore/), this pa-
tient has an 8% risk of experiencing a fatal cardiovascu-
lar event within 10 years. If this patient is IgM-RF
positive and has an RA duration of 10 years, we need
to multiply this risk by 1.5, which results in a 12% chance
of a fatal cardiovascular event within 10 years. Accord-
ing to several European guidelines, treatment with
statins and/or antihypertensive agents will be started
when the CVD risk score is 10%, provided that the
systolic blood pressure is 140 mm Hg and/or the
low-density lipoprotein (LDL) cholesterol level is 2.5
mmoles/liter (96.7 mg/dl).
We acknowledge that the multiplication factor of
1.5, which was derived from relevant standardized mor-
tality ratios, is a matter of debate, since there is a paucity
of prospective cohorts to enable the more usual ap-
proach to defining multiplication factors. A recent study
of general practitioners in the UK provided additional
support for a multiplication factor of 1.5 (31). Finally,
Crowson and colleagues (30) recently demonstrated that
cardiovascular risk appears to be most pronounced
among RA patients who are RF positive, older, and have
severe disease. Their findings are consistent with those
upon which the EULAR recommendations were based.
In summary, the increased CVD risk in RA is
indisputable and is due to both an excess of “traditional”
cardiovascular risk factors and the underlying chronic
inflammatory process. We acknowledge the need for
CVD prevention trials and RA-specific CVD risk pre-
diction charts, but we cannot wait the many years it
would take before these are available. We should incor-
porate cardiovascular risk management now—thereby
reducing the CVD risk burden in our patients—and
continue to evaluate its effectiveness over time.
In opposition, Dr. Dixon: Cardiovascular risk
intervention requires a balance of benefits, harms,
and cost-effectiveness
Evidence-based medicine has been defined as
“the conscientious, explicit, and judicious use of current
best evidence in making decisions about the care of
individual patients” (1). This definition incorporates the
use of clinical expertise and external evidence, in partic-
ular from patient-centered clinical research, in order to
come to optimal decisions about interventions for our
patients (1). Where there is a burden of disease, we need
to know with confidence how best to improve health.
It has been established that in patients with RA,
CVD rates are increased as compared to those in the
general population. This is manifested as an increased
incidence of myocardial infarction and stroke (2), and
increased rates of death from cardiovascular causes (3).
Guidelines assimilating and interpreting the expanding
data are welcome:15 new articles have been published
on this topic every month over the last 5 years (4). The
current EULAR guidelines (5), which were published 2
years ago, have already been cited over 200 times,
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reflecting the usefulness of synthesizing the evidence
into guideline form. Critically appraising the evidence
from all available sources is challenging, but vital, if we
are to understand whether we have a proven, effective
intervention for reducing cardiovascular risk that is
worth implementing in daily practice.
It can be helpful to separate the debate title into
a series of sequential questions. First, is cardiovascular
disease increased? (Answer: Yes—see above.) Second,
by what mechanism is CVD increased? Third, what is
the evidence that intervention lowers the risk of CVD,
and to what extent is it lowered? And last, is that
intervention worthwhile? Typically, the evidence base
weakens as we move through this series of questions.
Each of these questions will be explored in turn.
Cardiovascular risk in patients with RA is in-
creased by a variety of mechanisms, including both
traditional (smoking, hypertension, dyslipidemia) and
nontraditional (inflammation, medication) risk factors.
This topic has been reviewed extensively elsewhere (6,7).
Interventions can thus be targeted to many areas of
potentially increased risk. However, the multiple routes
from RA to increased CVD risk means that it cannot be
assumed that intervening in one pathway has a predict-
able clinical outcome. There are many examples where
pharmacologic interventions have had unpredictable,
bidirectional, or even paradoxical effects, for example,
increased suicidality with the use of antidepressants,
atypical femoral fractures with bisphosphonates, and
new-onset psoriaform lesions with anti-TNF therapy (8).
The debate must therefore focus on whether we have
sufficient evidence that an intervention targeted at one
of the many risk pathways truly reduces the burden of
CVD. Surrogate end points are useful, but the clinical
end points are the ones that matter.
What, then, is the evidence that intervention
lowers the incidence of CVD and to what extent is it
lowered? This can be considered with respect to inter-
ventions targeted at traditional cardiovascular risk fac-
tors and nontraditional risk factors. At present, there are
no published interventional studies (randomized con-
trolled trials [RCTs]) examining the efficacy of statins or
antihypertensive agents on clinical cardiovascular end
points exclusively in RA populations. Similarly, there are
no studies of weight reduction or smoking cessation
examining such end points in RA. There are therefore
no data from RCTs in this particular disease population
to support the use of these primary prevention mea-
sures. This does not mean that we have no information,
as we can extrapolate the results from other study
designs and other populations.
Observational studies of smoking cessation in
patients with coronary heart disease report a 36%
reduction in the relative risk of death in those who quit
as compared to those who continue to smoke (9). All
rheumatologists will accept guidelines that advise smok-
ing cessation in patients with RA, even though the
research was conducted in the general population. RCTs
of statins and antihypertensive agents have shown a clear
reduction of cardiovascular end points in populations
with existing CVD (secondary prevention). Evidence of
a positive impact weakens among populations with no
prevalent CVD (primary prevention). Statins have been
shown to have a positive effect in high-risk patients
without prevalent CVD, but caution is advised in pa-
tients with low cardiovascular risk (10). Primary preven-
tion of CVD in the low-risk general population is not
currently advocated because the background rate, and
thus, the absolute risk reduction, of cardiovascular dis-
ease is low. Many patients would need to be treated—
with the associated side effects and cost implications—in
order to avoid 1 case of CVD.
The difficult balance in RA rests here, among
patients with a lower baseline risk of CVD. Following
the evidence cited above, namely, that RA is estimated
to confer an additional 50% risk of CVD beyond that
conferred by the traditional risk factors, the EULAR
guidelines advocate multiplying an individual’s cardio-
vascular risk prediction score by 1.5 (5).This additional
risk can move an individual across the risk, and thus the
treatment, threshold. The example given in the recom-
mendations describes a female patient with traditional
risk factors that would confer a 7% risk of a fatal
cardiovascular event within 10 years in the general
population. That probability is then multiplied by 1.5
because of her RA, giving her a resultant 10-year risk of
experiencing a fatal cardiovascular event of 10.5%. This
moves her into a risk category that requires intervention.
Importantly, the advocated treatment at this
point is targeted to the traditional risk factors. But, is
this increased risk conferred by RA modifiable by inter-
ventions targeted to lipids or blood pressure? Might
statins work less well in RA patients than in the general
population because, say, inflammation drives CVD pro-
gression in RA more than lipid metabolism does? If
statins do have a positive effect, is this benefit seen at a
particular stage of disease? Might it be that, once the
increased CVD is established in RA, reducing lipid
levels can slow, but cannot reverse, the process? These
questions remain unanswered and frame the research
agenda in this area.
Another option for reducing CVD in patients
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with RA is to treat the nontraditional risk factors, such
as inflammation. There is evidence to support this. All
studies, bar one, in a recent meta-analysis showed a
reduced risk of cardiovascular events in patients treated
with methotrexate (overall relative risk 0.79 [95% con-
fidence interval 0.73–0.87]) (11). The magnitude of the
reduced risk is clinically meaningful. Although bias is
possible (such as residual confounding from steroid use),
a 20% cardiovascular risk reduction would be a welcome
consequence of treating the joint symptoms. Recom-
mendations cite this drug as having the best evidence for
risk reduction. While this may be true, we must be
cautious not to infer that methotrexate leads to a greater
risk reduction than sulfasalazine or leflunomide does.
There have been few studies examining the cardiovas-
cular effects of these treatments, and no comparative
studies. If we are to choose the optimal treatment that
reduces disease severity and cardiovascular risk, we need
to acquire this information.
Predicting the cardiovascular effects of anti-TNF
therapy is difficult because TNF is involved at many
stages of the pathophysiologic pathway (12). It may even
have bidirectional effects, for example, by reducing
inflammation but increasing lipid levels. Interestingly,
observational studies of cardiovascular outcomes follow-
ing anti-TNF therapy have led to discrepant, apparently
conflicting, results (for tabulation, see ref. 13). Reported
associations range from a 4–5-fold lower rate (14,15) to
a 70% increased rate of incident cardiovascular events
(16). One reason for the discrepancy becomes clear as
these studies are compared. Although all studies address
the influence of anti-TNF therapy on CVD in patients
with RA, no two studies have the same comparator
group, the same definition of cardiovascular outcome,
and adjust for the same confounders. Furthermore,
there are additional differences between studies in terms
of the penetration of drug use, the average disease
duration, and more. At present, we still do not know the
effects of anti-TNF therapy on cardiovascular outcomes.
Consensus in this area might be possible, but investiga-
tors need to work together to address comparable
research questions (17).
The last and most important question is whether
any intervention is worthwhile—ultimately, it is a bal-
ance of benefits, harms, and cost-effectiveness. This is
not always an easy balance, particularly since each
outcome is measured in different units and information
can be missing. Nevertheless, despite evidence gaps for
a range of questions in RA populations, we can still
be proactive in reducing cardiovascular risk. Lifestyle
changes, such as weight reduction and smoking cessa-
tion, offer a wealth of positive benefits, and so we must
continue (or start!) to provide such advice. Tight control
of disease activity has already been established as the
standard of care for patients with RA in order to
optimize the reduction of disease progression in their
joints. Cardiovascular benefits can be readily accepted as
an added benefit. However, intervening to treat tradi-
tional risk factors in patients with RA at a stage at which
intervention would not be advocated in the general
population does not yet have a supporting evidence
base. Before committing large numbers of RA patients
to such interventions, we need to have quantified the
benefits and harms.
In support, Dr. Peters and Nurmohamed: Rebuttal
Dr. Dixon begins his argument confirming that
RA patients are at increased cardiovascular risk. How-
ever, we must ask ourselves whether physicians are
aware of the increased cardiovascular risk conferred by
RA. A recent study suggests that there is poor cardio-
vascular risk management by primary care physicians as
well as rheumatologists. This clearly demonstrates the
need for better education to improve awareness of
cardiovascular risk in RA (32).
His argument continues by highlighting the fact
that cardiovascular risk in RA is attributed not only to
classic risk factors, but also to nonclassic risk factors,
including systemic inflammation and antirheumatic
treatment. The latter point about medications may com-
plicate our understanding of the role of RA-specific
treatment in cardiovascular risk in RA. While we agree
to some extent, this argument applies to almost all
diseases and therapeutic interventions. But, should we,
because of our lack of knowledge about its true effect on
the CVD burden in RA, avoid statin therapy in RA
patients at high risk of CVD? We respectfully disagree.
Dr. Dixon is right, in that the extrapolation of
intervention effects from non-RA patients to those with
RA is not supported by the findings of RCTs. However,
the same argument can be made about the use of many
treatments in groups that have been underrepresented
in trials, such as women and many ethnic minorities. We
should not withhold treatment of cardiovascular risk
factors from these patients if knowledge of the pathobi-
ology of CVD supports extrapolation of the findings of
large intervention trials. Such extrapolations are integral
to the practice of medicine, and the type of rationale to
support them is part of evidence-based medicine (33).
The only patient category at this time where extrapola-
tions of large cardiovascular intervention trials have
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failed are those with end-stage renal disease, who seem
to be “beyond repair” in terms of cardiovascular dam-
age. There is no rationale for why chronic inflammation
or other RA-related factors would render statins or
antihypertensive agents ineffective. This does not imply
that trials should not be performed, but it does mean
that RA patients should be given the benefit of the
doubt.
In addition, Dr. Dixon adds examples from sev-
eral pharmacologic interventions in which there were
potential adverse effects, for example, increased suicid-
ality with antidepressant therapy. Does this mean that
we should not treat patients who are depressed? Simi-
larly, should we avoid statin therapy in RA patients at
high risk of CVD because of its possible myopathy? We
disagree with this approach. Lack of data from RCTs on
the effects and/or side effects of statin therapy or other
cardiopreventive drugs in RA should not deter us from
trying to bring down the 50% higher risk of CVD in
patients with RA. Additionally, there are no data that
would lead us to believe that statin therapy is less
effective in RA, and the potential hazards of statin
therapy seem to be extremely small in relation to the
clear benefits in many circumstances (19,34). We concur
that specific trial data conducted in RA patients will
improve the evidence base on this clinically relevant
topic. Until such trials have been performed, however,
withholding cardiopreventive drugs that are very likely
to work in the RA population simply seems unethical.
Dr. Dixon’s debate position focuses on the lack of
evidence to support treatment of classic risk factors in
patients with RA at a stage where intervention would
not be advocated in the general population. Here, we
would like to emphasize that cardiovascular risk man-
agement in RA should be done according to national
guidelines, no different from that in the general popu-
lation; that is, only when the global 10-year risk of a fatal
cardiovascular event is 10% is treatment instituted at
the point when the blood pressure and/or lipid levels are
increased. Importantly, recently published data under-
score the fact that well-established CVD risk prediction
charts, such as the Framingham Risk Score and the
Reynolds Risk Score, underestimate the true cardiovas-
cular risk in patients with RA, indicating that the
(conservative) 1.5 multiplier is needed in order to make
an appropriate estimation of the true cardiovascular risk
in RA (30). To deal with this and because accurate
assessment of cardiovascular risk depends on the char-
acteristics of the RA, the EULAR task force favored
individualized risk assessment.
In conclusion, whichever approach is taken, the
recognition of RA as a cardiovascular risk factor is
important. Availability of simple CVD risk prediction
charts will lead to wider implementation of risk-
modification strategies in routine clinical care. The extrap-
olation of the favorable effects of statins and antihyper-
tensive agents to patients with RA is rational and
reasonable and is in perfect agreement with what David
Sackett described as an appropriate and comprehensive
definition of evidence-based medicine in the very same
paper Dr. Dixon uses as his first reference (33).
In opposition, Dr. Dixon: Rebuttal
There is significant overlap in the pro and con
positions in the first half of the debate. Readers might
even be forgiven for missing the area of contention
altogether. To illustrate, I agree with most of the con-
cluding paragraph of Drs. Peters and Nurmohamed’s
argument. We agree that (a) there is an increased risk of
CVD in patients with RA, (b) this risk is due to both an
excess of “traditional” cardiovascular risk factors and
the underlying chronic inflammatory process, and (c)
while there is a need for CVD prevention trials in RA as
well as RA-specific CVD risk prediction charts, we must
optimize the treatment we prescribe now. Where we
disagree is over which cardiovascular risk management
interventions should be incorporated, in whom, and
importantly, the focus of this debate, on what evidence?
Let me first underline our agreement concerning
cardiovascular risk management. Patients with RA who
fulfill general population criteria for cardiovascular risk
reduction should receive interventions (smoking cessa-
tion, weight reduction, blood pressure control, lipid-
lowering therapy), irrespective of their RA. Patients with
RA and obesity should be given advice about weight
management. While their arthritis might make exercise
more difficult, weight reduction should remain a goal.
Smokers should be encouraged to stop smoking, regard-
less of whether they have RA. Hypertension or dyslipi-
demia should also be treated, if appropriate, based on
absolute cardiovascular risk, using validated prediction
models such as the Framingham Risk Score. We all
agree that the absence of evidence for the reduction of
cardiovascular end points in the RA population should
not stop us from treating cardiovascular risk factors as
we would in the general population. We also agree that
we should treat active inflammation, which will not only
benefit the joint disease, but has also been proven to
have a beneficial effect on cardiovascular end points.
Which treatment has the most benefit for this important
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comorbid condition remains to be seen and should be
carefully investigated.
The critical gap in our knowledge is whether we
should treat cardiovascular risk factors in patients who
would not previously have fulfilled the criteria. Applying
a multiplication factor of 1.5 to a risk score of 8% would
tip some people beyond the treatment threshold, but is
this multiplication factor appropriate? Does RA gener-
ate its excess cardiovascular risk only by multiplying the
risk conferred by the traditional cardiovascular risk
factors, say cholesterol, as the algorithm suggests? If so,
targeting the cholesterol would be appropriate and
would remove the cardiovascular risk of RA. This mul-
tiplicative model assumes that RA acts solely via the
pathway of traditional risk factors through an aug-
mented effect of these established risks. We have al-
ready all agreed that this is not the case.
An alternative to the multiplicative model is that
RA is an additive risk factor. In other words, a raised
cholesterol level causes x additional heart attacks per
1,000 patients, and the presence of RA would add a
further y cases. Treating the raised cholesterol level in
this instance would have the same impact as it does in
the general population. Because such a treatment was
deemed inappropriate in large general population stud-
ies, it would be no more appropriate in patients with RA,
since the benefits, harms, and costs are unchanged. The
truth is likely to fall between these models, leaving
uncertainty about appropriate treatment in this group.
This is the difficult area where evidence is lack-
ing, to reiterate: patients who would not meet traditional
treatment thresholds for cardiovascular preventive treat-
ments, but who, by nature of their RA, are accepted to
be at higher risk. We need to know how best to intervene
to minimize their cardiovascular risk. But how can this
be determined? An RCT examining primary prevention
in RA using, say, statins and powered to detect cardio-
vascular end points would allow us to answer this
question. Indeed, the Trial of Atorvastatin for the
Primary Prevention of Cardiovascular Events in Patients
with Rheumatoid Arthritis (TRACE-RA) was estab-
lished in the UK to address just this question. However,
despite being the largest academically led RCT of RA in
the UK, the study was terminated early, after more than
3,000 patients of the 4,000 target population had been
recruited, due to a low incidence of the primary cardio-
vascular end point. Projected figures showed insufficient
power to reach a clear conclusion (Symmons D, Kitas G,
Belch J: personal communication). Despite its early
discontinuation, the fact that TRACE-RA patients (ir-
respective of treatment) had a low absolute risk of
cardiovascular end points is encouraging. Decisions
about the value of interventions are based on absolute
risk reduction or the number needed to treat. The low
overall incidence means that any difference between the
arms is less likely to be clinically meaningful.
If RCTs are impractical, how do we fill this gap in
knowledge? Observational research can measure the
impact of statins in patients with RA, but interpretation
of any results suffers from confounding by indication.
The treatment group is given statins for a particular
reason (dyslipidemia and or known CVD) and is thus
expected to have a higher risk of CVD compared to the
comparator group (no statins), who does not have
dyslipidemia or known CVD. One possible solution is to
run pragmatic trials within observational settings, ran-
domizing patients to treatment, then collecting informa-
tion on outcomes as part of routine clinical practice (18).
This will take a concerted effort across the rheumatology
community plus development of infrastructure, but it is
a goal worth pursuing.
This debate was framed around the evidence to
support treatment recommendations. Despite some dis-
cussion about the multiplication factor for risk predic-
tion and the treatment threshold, we agree on most
things. The 12–25% of patients with RA who currently
smoke (19) need to be encouraged to stop. Over half of
patients with RA have a body mass index of 25 kg/m2,
and 70% perform no regular physical activity (20).
Healthy lifestyles leading to a desirable body weight, a
healthy diet, regular exercise, and not smoking could
account for an 84% reduction in cardiovascular risk, and
yet, few people fall into this category (21). Focused
management of cardiovascular risk factors that warrant
intervention in the general population can make a big
difference in RA. Meanwhile, researchers should con-
tinue to explore the comparative effectiveness of treat-
ment with disease-modifying antirheumatic drugs for
cardiovascular end points and evaluate the balance of
benefits and harms for primary prevention in RA.
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